You are here: Industry Insights > opioid

News List

A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain ncbi
November 30, 2017
Chronic nonmalignant pain is a silent epidemic in the U.S. that affects approximately 116 million Americans.
Competing drugs to treat opioid addiction equally safe, according to study pharmaceutical-journal
November 28, 2017
In a randomised controlled trial in the US, extended-release naltrexone, also known as Vivitrol, and sublingual buprenorphine-naloxone, also known as Suboxone, were both found to be safe and effective.
EMA grants marketing authorisation for Zubsolv for opioid dependence pharmatimes
November 22, 2017
The European Medicines Agency (EMA) has granted a Marketing Authorization (MA) for Zubsolv (buprenorphine and naloxone), a novel rapidly-disintegrating treatment option for opioid dependence to Orexo AB (publ.) .
FDA grants marketing authorization of the first device for use in helping to reduce the symptoms fda
November 16, 2017
FDA permits marketing of the first device for use in helping to reduce the symptoms of opioid withdrawal
A vaccine for addiction? Don’t get your hopes up just yet: expert fiercepharma
August 15, 2017
Tom Price says an NIH vaccine for addiction is "an incredibly exciting prospect," but experts say it's far from reality.
Feds pull Mylan, a small-time opioid drugmaker, into industrywide marketing probe fiercepharma
August 11, 2017
The Department of Justice subpoenaed Mylan in July for information relating to its opioid business. At least two other drugmakers have disclosed similar demands this month.
New Hampshire, 'ground zero' of addiction epidemic, sues Purdue Pharma for overhyping opioids fiercepharma
August 10, 2017
New Hampshire sued Purdue Pharma for allegedly deceptive marketing on opioid painkillers.
FDA requests removal of certain prescription opioid for risks related to abuse cphi-online
June 12, 2017
Injection abuse of reformulated Opana ER has been associated with a serious outbreak of HIV and hepatit.is C
Ohio suit will be 'tough to win' for opioid drugmakers, analyst says fiercepharma
June 05, 2017
While opioid drugmakers have been sued plenty of times before, this week’s lawsuit from Ohio may prove a genuine threat to the companies involved, according to one influential analyst.
Camurus and Braeburn Pharmaceuticals announce positive top-line results from Phase 3 safety study of pharmaasia
May 17, 2017
New data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients with opioid use disorder.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page